


Besarab A, Frinak S, Yee J. What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway? Adv Chronic Kidney Dis. 2009;16(2):131-142.


Blajchman MA. Landmark studies that have changed the practice of Transfus Med. Transfusion. 2005;45:1523-1530.


Cohen D, Raia RM. Erythropoietin (EPO) requirements remain high in EPO resistant patients after iron repletion. ASAIO J. 1998;44:M596-M597.


Davies CB, Alexander JW, Cofer BR, First MR, Schroeder TJ. Efficacy of a single pretransplant donor-specific transfusion and cyclosporine A administered 24


El-Khatib M, Duncan HJ, Kant KS. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients. Nephrology. 2006;11:400-404.


Gee K, Guzzo C, Mat NFC, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009;8:40-52.


Grützmacher P, Scheuermann E, Löw I, Bergmann M, Rauber K, Baum R. Correction of renal anaemia by recombinant human erythropoietin: effects on


Keown PA. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. Contrib Nephrol. 1991;88:81-86;discussion 87-89.


Klein HG. How safe is blood, really? Biologicals. 2010;38:100-104.


McCarty MF. Hyperinsulinemia may boost both hematocrit and iron absorption by up-regulating activity of hypoxia-inducible factor-1α. Med Hypotheses. 2003;61(5-6):567-573.


Muirhead N, Hodsman AB, Holloby DJ, Cordy PE. The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients.


Nissim JA. Plasma iron levels after the intravenous administration of different iron preparations. J Physiol. 1952;118(4):63P-64P.

Nissim JA. Plasma iron levels and urinary iron excretion after the intravenous administration of different iron preparations. Br J Pharmacol. 1953;8:371-377.


Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life. Med Care. 2003;41:582-592.


Sekili S, McCay PB, Li X, Zughai M, Sun J, Tang L, Thornby JI, Bolli R. Direct evidence that the hydroxyl radical plays a pathogenetic role in myocardial “stunning” in the conscious dog and demonstration that stunning can be markedly attenuated without subsequent adverse effects. Circ Res. 1993;73:705-723.


Shander A, Sazama K. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. Transfusion. 2010;50:1144-1155.


Smith WB, Dowell JA, Pratt RD. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with


Strippoli GF. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials. 2010;11:70.


Sturm B, Laggner H, Ternes N, Goldenberg H, Scheiber-Mojdehkar. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable


